Offered through our partner laboratory, Adgyl Lifesciences
Eurofins Advinus via a partner laboratory Adgyl Lifesciences, delivers a robust and diverse portfolio of in vivo oncology and immuno-oncology models to support the development of novel anti-cancer therapies.
These preclinical models offer pharmaceutical and biotech companies valuable predictive insights before entering clinical trials accelerating drug development and informing effective treatment strategies.
Cell Line Derived Xenograft (CDX) Models
CDX models are extensively used to evaluate tumour growth dynamics, therapeutic efficacy, and biomarker discovery. Offered via Adgyl Lifesciences, our xenograft collection spans a broad range of human cancer types:
- Brain: U87MG, A172
- Breast: MCF-7, MDAMB-231, MDA-MB-453, MDA-MB-468, HCC1395, BT474
- Bladder: T24, HT-1376
- Colon: HT29, HCT116, DLD1, COLO-205
- Epidermoid: A431
- Gastric: N87
- Lung: A549, H1975, NCI-H358, NCI-H727
- Liver: HepG2, JHH7
- Kidney: ACHN
- Melanoma: A375, SK-MEL-28
- Prostate: PC3, LNCaP, VCaP, VCaP-ENZ
- Pancreas: BxPC-3, MIA PaCa-2
- Ovary: SKOV-3
- Medulloblastoma: D283
- Tongue: CAL27
Syngeneic & Immuno-Oncology (IO) Models
Developed using murine tumour cells in immunocompetent mice, syngeneic models are vital for evaluating immune-tumour interactions and immunotherapy mechanisms. Our key IO models include:
- Fibrosarcoma: MCA205, WEHI-164
- Breast Cancer: 4T1, EMT6
- Colon Cancer: CT26.WT, MC-38
- Kidney Cancer: Renca
- Lung Cancer: LL/2
- Melanoma: B16-F10
- Myeloma: J558
Humanized Mice Models
These advanced models enable the evaluation of human immune responses to cancer therapies. Eurofins Advinus, via Adgyl Lifesciences, offers:
- Melanoma (A-375 xenograft) in humanized immune settings
Orthotopic Models (Human & Murine)
Orthotopic models offer a more physiologically relevant tumor environment by placing cancer cells in their organ-specific locations. Available models include:
- Colon: DLD1, HT29, HCT116, COLO-205
- Breast: MDAMB-231, 4T1, EMT6
- Pancreas: MiaPaCa2, BxPC-3
- Bladder: T24, NBT-II
- Brain: U87MG, A172
- Ovary: SKOV-3
- Liver: HepG2
- Lung: A549, H1975
- Prostate: PC3, LNCaP, VCaPc
Metastasis Models (Human & Murine)
Understanding how cancer spreads is key to designing therapies that limit metastasis. Our metastasis models help simulate this process:
- Breast: 4T1
- Lung: A549, LLC
- Melanoma: B16F10
- Fibrosarcoma: MCA 205
Angiogenesis Assay
Tumour vascularization is a critical target in oncology. Our Matrigel plug angiogenesis assay evaluates how experimental drugs inhibit or promote new blood vessel formation in tumour microenvironments.
Leukaemia & Lymphoma Models
Eurofins Advinus, via Adgyl Lifesciences, offers in vivo models for haematological malignancies including:
- Acute Myeloid Leukaemia (AML): THP1, HL60
- Chronic Myelogenous Leukaemia (CML): K562
- Lymphoma: H929, U937, Raji
Disseminated Disease Models
To assess the systemic impact of therapies for blood cancers, we provide disseminated models for:
- Leukaemia: HL-60
- Lymphoma: U-937
Why Choose Our In Vivo Oncology & IO Models?
Predictive Accuracy: Our models simulate human cancer biology with high translational relevance
Comprehensive Portfolio: Coverage across solid tumours, blood cancers, and immune-oncology applications
Customizable Solutions: Study designs tailored to unique scientific or regulatory goals
Scientific Expertise: Dedicated scientific support from model selection through to data interpretation
Frequently Asked Questions (FAQs)
What are in vivo oncology and immuno-oncology models?
These are preclinical (animal-based) systems used to study cancer progression and evaluate how new drugs or immunotherapies perform in a living organism.
How do CDX, syngeneic, and humanized models differ?
- CDX Models: Use human cancer cells in immunocompromised mice to study tumour behavior and treatment effects.
- Syngeneic Models: Employ mouse cancer cells in immunocompetent mice—ideal for studying immune system responses.
- Humanized Models: Feature a human-like immune system to test therapies that depend on human immune mechanisms.
Why are orthotopic models important?
They place cancer cells into the original organ site (e.g., lung cancer cells in the lungs), offering more clinically relevant data than subcutaneous models.
What’s the value of metastasis models?
They help assess how cancers spread and whether therapies can prevent secondary tumour formation—critical for improving survival outcomes.
What is an angiogenesis assay?
This test evaluates how a therapy affects the formation of blood vessels, a key process that tumours use to grow and spread.
Accelerate Your Oncology Research with Confidence
With access to a diverse and validated set of in vivo models through Adgyl Lifesciences and the scientific expertise of Eurofins Advinus, you can confidently advance your oncology and immuno-oncology pipeline with data that drives decisions and meets global standards.